JAK1 and chronic myelogenous leukemia, BCR-ABL1 positive: For instance, BM-MSCs protect CML cells from imatinib-induced cell death, mediated by MSC-secreted IL-7 and activation of the JAK1-STAT5 pathway CML cells.